Aggressive dream content without daytime aggressiveness in REM sleep behavior disorder.
M L Fantini, A Corona, S Clerici...
https://pubmed.ncbi.nlm.nih.gov/16217051Actively Recruiting
Led by University of Cagliari · Updated on 2024-03-26
300
Participants Needed
2
Research Sites
513 weeks
Total Duration
U
University of Cagliari
Lead Sponsor
U
University of Bologna
Collaborating Sponsor
REM Sleep Behavior Disorder (RBD) is a condition where the normal muscle paralysis during REM sleep is lost, causing abnormal and sometimes violent movements often linked to dreams. This disorder can exist on its own, called idiopathic RBD (iRBD), or be associated with neurological diseases like Parkinson's Disease and Lewy Body Dementia. Researchers are studying RBD to understand its progression and to identify markers that predict when iRBD patients may develop related neurodegenerative diseases, as well as to characterize different patient subtypes and quality of life impacts. The study is observational and collects clinical, biological, neurophysiological, neuropsychological, and imaging data from participants diagnosed with iRBD. These data are gathered using standardized and harmonized procedures to identify predictive risk factors and distinct phenotypes of iRBD. The goal is to create a well-characterized group of patients ready for future trials of disease-modifying therapies, including monoclonal antibodies targeting alpha-synucleinopathies. Participants will be followed over many years, with assessments including video-polysomnographic recordings (vPSG), clinical exams, questionnaires, and imaging tests. Researchers will track the development of alpha-synucleinopathies, quality of life changes, and correlations between muscle activity loss during REM sleep and cognitive performance. The primary outcome is identifying risk factors for disease progression, with monitoring continuing through January 2035 to capture long-term data on conversion rates and patient well-being.
CONDITIONS
PREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 14 years
Participants diagnosed with idiopathic REM Sleep Behavior Disorder are observed over an extended period to collect longitudinal data and evaluate changes in condition and quality of life.
Regular visits for assessments over several years
Total: 2 locations
1
IRCCS Auxologico Piancavallo
Oggebbio, Verbania, Italy, 28824
Actively Recruiting
2
Centro Interdipartimentale di Medicina del Sonno, Università degli studi di Cagliari
Cagliari, Italy, 09042
Actively Recruiting
M
Monica Puligheddu, MD, PhD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
M L Fantini, A Corona, S Clerici...
https://pubmed.ncbi.nlm.nih.gov/16217051D Oudiette, V C De Cock, S Lavault...
https://pubmed.ncbi.nlm.nih.gov/19204265Carlos H Schenck, Mark W Mahowald
https://pubmed.ncbi.nlm.nih.gov/11902423Birgit Frauscher, Alex Iranzo, Carles Gaig...
https://pubmed.ncbi.nlm.nih.gov/22654203Julius B M Anang, Jean-Francois Gagnon, Josie-Anne Bertrand...
https://pubmed.ncbi.nlm.nih.gov/25171928Julius B M Anang, Takashi Nomura, Silvia Rios Romenets...
https://pubmed.ncbi.nlm.nih.gov/27911340Elena Sinforiani, Claudio Pacchetti, Roberta Zangaglia...
https://pubmed.ncbi.nlm.nih.gov/18512749Ronald B Postuma, Jean-Francois Gagnon, Melanie Vendette...
https://pubmed.ncbi.nlm.nih.gov/18709686Ronald B Postuma, Jean-Francois Gagnon, Josie-Anne Bertrand...
https://pubmed.ncbi.nlm.nih.gov/25681454Seyed-Mohammad Fereshtehnejad, Silvia Rios Romenets, Julius B M Anang...
https://pubmed.ncbi.nlm.nih.gov/26076039